GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ARIAD Pharmaceuticals Inc (NAS:ARIA) » Definitions » Operating Income

ARIAD Pharmaceuticals (ARIAD Pharmaceuticals) Operating Income : $-137.1 Mil (TTM As of Sep. 2016)


View and export this data going back to 1994. Start your Free Trial

What is ARIAD Pharmaceuticals Operating Income?

ARIAD Pharmaceuticals's Operating Income for the three months ended in Sep. 2016 was $-25.0 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Sep. 2016 was $-137.1 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. ARIAD Pharmaceuticals's Operating Income for the three months ended in Sep. 2016 was $-25.0 Mil. ARIAD Pharmaceuticals's Revenue for the three months ended in Sep. 2016 was $46.0 Mil. Therefore, ARIAD Pharmaceuticals's Operating Margin % for the quarter that ended in Sep. 2016 was -54.31%.

ARIAD Pharmaceuticals's 5-Year average Growth Rate for Operating Margin % was 0.00% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. ARIAD Pharmaceuticals's annualized ROC % for the quarter that ended in Sep. 2016 was -25.19%. ARIAD Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2016 was -28.52%.


ARIAD Pharmaceuticals Operating Income Historical Data

The historical data trend for ARIAD Pharmaceuticals's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ARIAD Pharmaceuticals Operating Income Chart

ARIAD Pharmaceuticals Annual Data
Trend Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15
Operating Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only -76.82 -205.06 -273.57 -160.20 -217.28

ARIAD Pharmaceuticals Quarterly Data
Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16
Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -56.38 -52.59 -47.86 -11.66 -24.99

ARIAD Pharmaceuticals Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Sep. 2016 adds up the quarterly data reported by the company within the most recent 12 months, which was $-137.1 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ARIAD Pharmaceuticals  (NAS:ARIA) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

ARIAD Pharmaceuticals's annualized ROC % for the quarter that ended in Sep. 2016 is calculated as:

ROC % (Q: Sep. 2016 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2016 ) + Invested Capital (Q: Sep. 2016 ))/ count )
=-99.96 * ( 1 - 7.74% )/( (357.616 + 374.604)/ 2 )
=-92.223096/366.11
=-25.19 %

where

Invested Capital(Q: Jun. 2016 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=624.367 - 60.294 - ( 278.544 - max(0, 100.663 - 307.12+278.544))
=357.616

Invested Capital(Q: Sep. 2016 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=676.591 - 61.591 - ( 314.665 - max(0, 110.843 - 351.239+314.665))
=374.604

Note: The Operating Income data used here is four times the quarterly (Sep. 2016) data.

2. Joel Greenblatt's definition of Return on Capital:

ARIAD Pharmaceuticals's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2016 is calculated as:

ROC (Joel Greenblatt) %(Q: Sep. 2016 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2016  Q: Sep. 2016
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-86.964/( ( (300.962 + max(-47.565, 0)) + (308.966 + max(-44.255, 0)) )/ 2 )
=-86.964/( ( 300.962 + 308.966 )/ 2 )
=-86.964/304.964
=-28.52 %

where Working Capital is:

Working Capital(Q: Jun. 2016 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(14.106 + 0.903 + 13.567) - (60.294 + 10.55 + 5.297)
=-47.565

Working Capital(Q: Sep. 2016 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(23.975 + 2.061 + 10.538) - (61.591 + 10.89 + 8.348)
=-44.255

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2016) EBIT data.

3. Operating Income is also linked to Operating Margin %:

ARIAD Pharmaceuticals's Operating Margin % for the quarter that ended in Sep. 2016 is calculated as:

Operating Margin %=Operating Income (Q: Sep. 2016 )/Revenue (Q: Sep. 2016 )
=-24.99/46.016
=-54.31 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.


Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


ARIAD Pharmaceuticals Operating Income Related Terms

Thank you for viewing the detailed overview of ARIAD Pharmaceuticals's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.


ARIAD Pharmaceuticals (ARIAD Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
ARIAD Pharmaceuticals Inc was organized as a Delaware corporation in April 1991. It is an oncology company. The Company is focused on discovery and development of breakthrough medicines to treat cancers by regulating cell signaling with small molecules. The Company's first approved cancer medicine, Iclusig (ponatinib), and its product candidates, AP26113 and ridaforolimus, were discovered internally by its scientists based on the expertise in computational and structure-based drug design. AP26113 is an investigational inhibitor of anaplastic lymphoma kinase, or ALK. In non-clinical studies, AP26113 also demonstrated that it can inhibit epidermal growth factor receptor, or EGFR, and c-ros oncogene-1, or ROS1. . Iclusig and its drug candidates and preclinical compounds are small molecules that can be readily synthesized by processes that it has developed. The Company do not own or operate manufacturing facilities for the production of clinical or commercial quantities of Iclusig or its product candidates. The company's competitors includes pharmaceutical and biotechnology companies such as Amgen Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, Celgene Corporation, Eli Lilly and Company, the Roche Group, GlaxoSmithKline plc, Johnson & Johnson, Merck, Merck KGaA, Novartis AG, Pfizer, Inc., Sanofi-Aventis, Takeda Pharmaceutical Co., Ltd., and Teva Pharmaceutical Industries Ltd.Inc.
Executives
Alexander J Denner director C/O SARISSA CAPITAL MANAGEMENT LP, 660 STEAMBOAT ROAD, 3RD FLOOR, GREENWICH CT 06830
Norbert G Riedel director BAXTER INTERNATIONAL INC, ONE BAXTER PKWY DF2-1W, DEERFIELD IL 60015
Elona Esq. Kogan officer: Sr. V. P. - General Counsel C/O SEER, INC., 3800 BRIDGE PARKWAY, SUITE 102, REDWOOD CITY CA 94065
Manmeet Singh Soni officer: EVP, CFO & Treasurer C/O PHARMACYCLICS, INC., 995 EAST ARQUES AVE, SUNNYVALE CA 94085
Timothy P Clackson officer: President, R&D, CSO C/O ARIAD PHARMACEUTICALS INC, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Jules Haimovitz director 601 108TH AVENUE NE, SUITE 1200, BELLEVUE WA 98004
Daniel M Bollag officer: Sr. VP, Reg. Affairs & Quality C/O ARIAD PHARMACEUTICALS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Hugh M Cole officer: SVP, Chief Business Officer C/O ARIAD PHARMACEUTICALS, INC, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
George Bickerstaff director C/O VION PHARMACEUTICALS, INC., 4 SCIENCE PARK, NEW HAVEN CT 06511
Paris Panayiotopoulos director, officer: President and CEO ARIAD PHARMACEUTICALS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Anna Protopapas director MILLENNIUM PHARMACEUTICALS, INC., 40 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Sarah J. Schlesinger director C/O ARIAD PHARMACEUTICALS, 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Massimo Radaelli director C/O ARIAD PHARMACEUTICALS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139
Martin J Duvall officer: EVP, CCO MGI PHARMA, INC., 5775 WEST OLD SHAKOPEE ROAD, SUITE 100, BLOOMINGTON MN 55437
Frank Haluska officer: SVP, Clinical R&D, CMO C/O ARIAD PHARMACEUTICALS, INC., 26 LANDSDOWNE STREET, CAMBRIDGE MA 02139

ARIAD Pharmaceuticals (ARIAD Pharmaceuticals) Headlines

From GuruFocus